Accustem Sciences (ACUT) Cash from Investing Activities (2022)
Accustem Sciences (ACUT) posted quarterly Cash from Investing Activities of -$2796.0 for Q2 2022, up 65.91% quarter-over-quarter from -$8203.0 in Q1 2022.
Accustem Sciences (ACUT) Cash from Investing Activities (2022) Analysis & Trends
Accustem Sciences (ACUT) has reported Cash from Investing Activities for 1 consecutive years, with -$2796.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Cash from Investing Activities changed N/A year-over-year to -$2796.0; the TTM figure through Dec 2022 stood at -$10999.0 (changed N/A YoY), while the FY2022 annual figure was -$10999.0, changed N/A from the prior year.
- Cash from Investing Activities improved to -$2796.0 in Q2 2022 per ACUT's latest filing, from -$8203.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$2796.0 in Q2 2022 and bottomed at -$8203.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -2,796.00 |
| Jun 30, 2022 | -2,796.00 |
| Mar 31, 2022 | -8,203.00 |
| Mar 31, 2022 | -8,203.00 |